Emergent BioSolutions Inc.
NYSE:EBSBiotechnology
-$0.21 today
- Market cap
- $282.78M
- Beta
- 2.33
- P/E (TTM)
- -47.9
- EPS (TTM)
- -$0.17
Volume 0.82M
Average 0.78M
EBS Inventory
Raw materials, work in progress, and finished goods held for sale.
Emergent BioSolutions Inc.NYSE: EBS
Inventory · Q1 FY2026 · quarter ended Mar 2026
Inventory rises 4.3% from a year ago
Inventory stood at $327.6M at the end of Q1 FY2026, up 4.3% from a year earlier and down 4.6% from the prior quarter. Over 3 fiscal years it compounded at -0.7% a year.
Context
- Inventory amounted to 24.8% of total assets at the end of Q1 FY2026, up 2.8 pp from a year earlier.
- Inventory increased in 1 of the last 3 fiscal years.
What to watch
Whether inventory keeps rising in the next quarterly balance sheet after a +4.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Inventory history
USD · from the balance sheet
- Latest · FY2025
- 343.4M USD
- Year-over-year change
- +10.2%
- 4-year CAGR
- -0.1%
| Period | Period end | Inventory | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 343.4M | +10.2% |
| FY2024 | 2024-12-31 | 311.7M | -5.2% |
| FY2023 | 2023-12-31 | 328.9M | -6.2% |
| FY2022 | 2022-12-31 | 350.7M | +1.8% |
| FY2021 | 2021-12-31 | 344.5M | — |
Inventory vs competitors
How EBS compares with its peers on the latest reported figures
- Peers report in different currencies, so inventory is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +4.3% is the 4th highest of 7, against a peer median of +3.2%.
- Inventory amounts to 24.8% of total assets for EBS, versus a peer median of 3.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $327.6M USD | +4.3% | -0.7% | 24.8% | |
| Mar 2026 | CA$137.85M CAD | +1.4% | -0.3% | 10.5% | |
| Mar 2026 | $104.21M USD | +4.9% | +44.0% | 22.5% | |
| Mar 2026 | $56.49M USD | -4.3% | +7.7% | 25.8% | |
| Mar 2026 | $28.43M USD | -3.1% | +6.1% | 5.5% | |
| Mar 2026 | $11.65M USD | +150.1% | +8.1% | 2.3% | |
| Mar 2026 | $8.07M USD | +12.1% | +2.2% | 5.7% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding EBS) | — | +3.2% | +6.9% | 3.9% | |
Competitors are the stored peer set for EBS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 576.3M | 642.6M | 111.7M | 99.5M | 205.4M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 278.9M | 159.2M | 191M | 154.5M | 84.2M |
| Inventory | 344.5M | 350.7M | 328.9M | 311.7M | 343.4M |
| Other Current Assets | 70.2M | 57.9M | 47.9M | 33M | 29.5M |
| Total Current Assets | 1.27B | 1.21B | 679.5M | 598.7M | 662.5M |
| Property, Plant & Equipment (Net) | 828.4M | 837M | 399M | 270.6M | 205.4M |
| Goodwill | 224.9M | 218.2M | 0 | 0 | 0 |
| Intangible Assets | 604.6M | 728.8M | 566.6M | 501.5M | 436.5M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 29.9M | 171.9M | 178.1M | 18.9M | 14.2M |
| Total Non-current Assets | 1.69B | 1.96B | 1.14B | 791M | 656.1M |
| Total Assets | 2.96B | 3.17B | 1.82B | 1.39B | 1.32B |
| Account Payables | 128.9M | 103.5M | 112.2M | 60.9M | 55.6M |
| Short-term Debt | 37.4M | 963.1M | 413.7M | 2.7M | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 11.7M | 26.4M | 0 | 0 | 0 |
| Other Current Liabilities | 107.3M | 48.6M | 106.8M | 81.1M | 76.6M |
| Total Current Liabilities | 374M | 1.23B | 651.3M | 162.4M | 132.2M |
| Long-term Debt | 809.4M | 448.5M | 446.5M | 663.7M | 572.1M |
| Deferred Tax Liabilities | 93.3M | 59.7M | 47.2M | 41.7M | 37.8M |
| Deferred Revenue (Non-current) | 4.7M | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 40.6M | 26.7M | 28.9M | 29.4M | 53.9M |
| Total Non-current Liabilities | 972.2M | 549.7M | 522.6M | 744.5M | 663.8M |
| Total Liabilities | 1.35B | 1.78B | 1.17B | 906.9M | 796M |
| Common Stock | 100K | 100K | 100K | 100K | 100K |
| Retained Earnings | 950.3M | 738.7M | (21.8M) | (212.4M) | (159.8M) |
| Accumulated OCI | (16.1M) | 3.1M | (5.7M) | (5.2M) | (7.5M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 1.61B | 1.39B | 649.3M | 482.8M | 522.6M |
| Total Debt | 871M | 1.43B | 860.2M | 676.1M | 572.1M |
| Net Debt | 294.7M | 783.8M | 748.5M | 576.6M | 366.7M |
Emergent BioSolutions Inc.
NYSE:EBS
Intrinsic Alpha fair value
Locked
Current Price
$5.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.